Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 2
1974 1
1975 3
1983 1
1989 2
1990 2
1991 1
1993 1
1994 1
1999 1
2000 3
2001 2
2002 3
2003 2
2004 5
2005 1
2006 4
2007 3
2008 6
2009 3
2010 9
2011 7
2012 12
2013 14
2014 22
2015 18
2016 23
2017 30
2018 38
2019 38
2020 41
2021 49
2022 43
2023 44
2024 50
2025 39

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

446 results

Results by year

Filters applied: . Clear all
Page 1
Kidney Parameters with Tirzepatide in Obesity with or without Type 2 Diabetes.
Heerspink HJL, Friedman AN, Bjornstad P, van Raalte DH, Cherney D, Cao D, Garcia-Pérez LE, Stefanski A, Turfanda I, Bunck MC, Benabbad I, Griffin R, Piras de Oliveira C. Heerspink HJL, et al. Among authors: cherney d. J Am Soc Nephrol. 2025 Jun 13. doi: 10.1681/ASN.0000000764. Online ahead of print. J Am Soc Nephrol. 2025. PMID: 40512543
Adjunct-to-insulin therapy using SGLT2 inhibitors in youth with type 1 diabetes: a randomized controlled trial.
Mahmud FH, Bjornstad P, Clarson C, Clarke A, Anthony SJ, Curtis J, Elia YT, McArthur L, Mertens L, Moineddin R, Kirsch S, Coles N, Maione M, Furman M, Babalola F, Tommerdahl KL, Harrington J, Riddell MC, Prasad P, Huang L, Heerspink HJL, Cherney DZI. Mahmud FH, et al. Among authors: cherney dzi. Nat Med. 2025 Jun 6. doi: 10.1038/s41591-025-03723-6. Online ahead of print. Nat Med. 2025. PMID: 40481206
Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trial.
Beernink JM, Jongs N, Mosterd CM, Scholtes RA, Caldwell-McGee A, Casillas D, Driscoll L, Greasley PJ, Karlsson C, Hammarstedt A, Sridhar VS, Muskiet MHA, Laverman GD, Cherney DZI, Bjornstad P, van Raalte DH, Heerspink HJL. Beernink JM, et al. Among authors: cherney dzi. Diabetes Obes Metab. 2025 May 30. doi: 10.1111/dom.16478. Online ahead of print. Diabetes Obes Metab. 2025. PMID: 40444388
Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono- and combination therapy compared to gliclazide in overweight people with type 2 diabetes (RACELINES): A randomised, double-blind trial.
van Baar MJB, Muskiet MHA, Scholtes RA, Touw DJ, Nieuwdorp M, Kramer MHH, Joles JA, Cherney DZI, Bjornstad P, Krebber MM, van Raalte DH. van Baar MJB, et al. Among authors: cherney dzi. Diabetes Obes Metab. 2025 Jul;27(7):3943-3956. doi: 10.1111/dom.16431. Epub 2025 May 6. Diabetes Obes Metab. 2025. PMID: 40326063 Free PMC article. Clinical Trial.
SGLT2 Inhibitors and Risk for Hyperkalemia Among Individuals Receiving RAAS Inhibitors.
Wing S, Ray JG, Yau K, Jeyakumar N, Abdullah S, Luo B, Cherney DZI, Harel Z, Hundemer GL, Mavrakanas TA, Molnar AO, Odutayo A, Perl J, Young A, Charytan D, Weir M, Wald R. Wing S, et al. Among authors: cherney dzi. JAMA Intern Med. 2025 Apr 28:e250686. doi: 10.1001/jamainternmed.2025.0686. Online ahead of print. JAMA Intern Med. 2025. PMID: 40293730
Mechanistic evaluation of ertugliflozin in patients with type 2 diabetes and heart failure.
Lytvyn Y, Scholtes RA, Boorsma EM, Sridhar VS, Kugathasan L, Liu H, Lovblom LE, Handoko L, Mosterd CM, Floras JS, Burns K, Osuntokun T, Voors A, van Raalte DH, Heerspink HJL, Cherney DZI. Lytvyn Y, et al. Among authors: cherney dzi. Physiol Rep. 2025 Apr;13(7):e70275. doi: 10.14814/phy2.70275. Physiol Rep. 2025. PMID: 40207988 Free PMC article. Clinical Trial.
Cardiovascular disease in chronic kidney disease.
Marx-Schütt K, Cherney DZI, Jankowski J, Matsushita K, Nardone M, Marx N. Marx-Schütt K, et al. Among authors: cherney dzi. Eur Heart J. 2025 Apr 8:ehaf167. doi: 10.1093/eurheartj/ehaf167. Online ahead of print. Eur Heart J. 2025. PMID: 40196891
Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.
Mayne KJ, Sardell RJ, Staplin N, Judge PK, Zhu D, Sammons E, Cherney DZI, Cheung AK, Maggioni AP, Nangaku M, Rossello X, Tuttle KR, Ihara K, Iwata T, Wanner C, Emberson J, Preiss D, Landray MJ, Baigent C, Haynes R, Herrington WG; EMPA-KIDNEY Collaborative Group. Mayne KJ, et al. Among authors: cherney dzi. Clin J Am Soc Nephrol. 2024 Sep 1;19(9):1119-1129. doi: 10.2215/CJN.0000000000000498. Epub 2024 Jun 27. Clin J Am Soc Nephrol. 2024. PMID: 40179340 Clinical Trial.
446 results